Published: Published: November 28, 2011
- 45 pages Introduction F. Hoffmann-La Roche Ltd Sangamo BioSciences, Inc Kamada Ltd. October 13, 2011: Sangamo announced the publication in the nature of gene correction strategy of Alpha-1 antitrypsin deficiency
October 11, 2011: Isis Isis Select-AATRx consider AATD-Associated Liver Disease
March 23, 2011: Novartis announces FDA to regulate the expansion consideration during QAB149
February 14, 2011: Kamada Announces successful Interim Report of Phase II-III clinical trials of Inhaled Alpha-1 antitrypsin
October 25, 2010 : Baxter manufactures GLASSIA U.S.
October 25, 2010: Baxter manufactures GLASSIA U.S.
October 12, 2010: BioRx is Alpha-1 Custom Home Infusion Market
August 26, 2010: Baxter International, Inc acquires exclusive distribution rights Kamadas Glassi alpha-1 treatment increased in Canada
August 26, 2010: Baxter International, Inc acquires exclusive rights to distribute Kamadas Glassi alpha-1 treatment increased in Canada
August 24, 2010: Baxter Announces Production, supply and distribution agreement with Kamada for Glassia
Appendix List of Tables Number of products under development for emphysema, H2 2011
Products under development of emphysema - a comparative analysis, H2 2011
Number of products development stage companies, H2 2011
purchases of goods under investigation universities / institutes, H2 2011
comparative analysis at a late stage, H2 2011
comparative analysis by mid-clinical development stage, H2 2011
Comparative analysis of early clinical development stage, H2 2011
comparative analysis of preclinical stages of development, H2 2011
Products Development companies, H2 2011
Products under investigation universities / institutes, H2 2011
F. Hoffmann-La Roche Ltd, H2 2011
Sangamo Biosciences, Inc, H2 2011
Talecris Biotherapeutics Holdings Corp, H2 2011
Kamada Ltd., H2 2011
Applied Genetic Technologies Corporation, H2 2011
Intrexon Corporation, H2 2011
Score monotherapy products, H2 2011
Score stages and routes of entry, H2 2011
Score by molecule type, H2 2011
List of figures Shopping Cart in the development of emphysema, H2 2011
Products for the development of emphysema - a comparative analysis, H2 2011
Products Development companies, H2 2011 Production
under investigation universities / institutes, H2 2011
Late stage products, H2 2011
Mid-stage clinical products, H2 2011
early stage clinical products, H2 2011
preclinical stage products, H2 2011
Score monotherapy products, H2 2011
Evaluation of combination products, H2 2011
Score by way of entry, H2 2011
Score stages and routes of entry, H2 2011
ratings molecule type, H2 2011
Score on the stage and type of molecules, H2 2011
Emphysema - pipeline inspection, H2 2011
Summary Global Markets instructs, "Emphysema - pipeline inspection, H2 2011" provides overview Emphysema therapeutic pipeline. This report provides information on the therapeutic development of emphysema, complete with the latest updates, and special functions at a late stage, and terminated projects.
It also discusses key players involved in the therapeutic development of emphysema. "Emphysema - pipeline inspection, H2 2011" is built using data and information sourced from Global Markets directing their own websites databases, company / university, SEC filings, investor presentations and featured press releases / sites of universities and industry third-party sources gathered on the world market leads the team. * Note: Some sections of the report may be deleted or changed depending on the availability and relevance of data for these diseases. Field image of the global therapeutic scenario emphysema. Overview of Emphysema products under development companies and universities / research institutes based on information obtained from company and industry sources. Coverage of products based on different stages of development, from discovery to registration stages. Function pipeline projects on the basis of monotherapy and combination therapy. Lighting Emphysema pipeline on the basis of route of administration and molecule type. Profiles late stage pipeline products with sections on product description, mechanism of action and research and progress in development. The main stop pipeline projects. The latest news and deals related products. Reasons for buying identify and understand important and different types of therapy of emphysema. Identification of new players with potentially strong product portfolio and develop effective strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying the player with the most promising. Develop remedial measures for pipeline projects, understanding the depth of the pipeline and focus Emphysema Emphysema therapy. Development and design center licensing and licensing strategy by identifying potential partners with the most attractive projects to strengthen and expand business potential and opportunities. Change lasix no prescritpion the therapeutic portfolio by identifying the termination of projects and understanding the factors that led them from the pipeline. .
No comments:
Post a Comment